Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced it will release its full-year 2024 financial results on Friday, February 28, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day to discuss results and provide a business update. An archived replay will be available on the company's website following the conference.
Longeveron (NASDAQ: LGVN), una società biotecnologica nel settore della medicina rigenerativa in fase clinica, ha annunciato che pubblicherà i suoi risultati finanziari per l'intero anno 2024 venerdì 28 febbraio 2025, dopo la chiusura del mercato statunitense. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale. Una registrazione archiviata sarà disponibile sul sito web dell'azienda dopo la conferenza.
Longeveron (NASDAQ: LGVN), una empresa de biotecnología en etapa clínica dedicada a la medicina regenerativa, ha anunciado que publicará sus resultados financieros del año completo 2024 el viernes 28 de febrero de 2025, después del cierre del mercado estadounidense. La empresa llevará a cabo una conferencia telefónica y un webcast a las 4:30 p.m. ET el mismo día para discutir los resultados y proporcionar una actualización empresarial. Una grabación archivada estará disponible en el sitio web de la empresa después de la conferencia.
Longeveron (NASDAQ: LGVN), 임상 단계의 재생 의학 생명공학 회사가 2024 회계연도 전년도 재무 결과를 2025년 2월 28일 금요일, 미국 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 전화 회의 및 웹캐스트를 개최할 예정입니다. 회의 후 회사 웹사이트에서 아카이브된 재생이 제공될 것입니다.
Longeveron (NASDAQ: LGVN), une entreprise de biotechnologie spécialisée dans la médecine régénérative en phase clinique, a annoncé qu'elle publiera ses résultats financiers de l'année 2024 le vendredi 28 février 2025, après la clôture du marché américain. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30 ET le même jour pour discuter des résultats et fournir une mise à jour sur les activités. Une rediffusion archivée sera disponible sur le site web de l'entreprise après la conférence.
Longeveron (NASDAQ: LGVN), ein biotechnologisches Unternehmen im klinischen Stadium der regenerativen Medizin, hat angekündigt, dass es am Freitag, den 28. Februar 2025, nach Börsenschluss in den USA seine Jahresfinanzberichte 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu diskutieren und ein Unternehmensupdate bereitzustellen. Eine archivierte Wiedergabe wird nach der Konferenz auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
MIAMI, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
Conference Call and Webcast Details:
| Conference Call Number: | 1.877.407.0789 |
| Conference ID: | 13751432 |
| Call meTM Feature: | Click Here |
| Webcast: | Click Here |
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-BTM development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When will Longeveron (LGVN) release its full-year 2024 financial results?
What time is Longeveron's (LGVN) earnings call for full-year 2024 results?
Where can I access the replay of Longeveron's (LGVN) 2024 earnings call?
What will be discussed in Longeveron's (LGVN) February 28, 2025 conference call?
